Il SerD come Point of Care per infezione da HCV: è possibile

Author:

Praticò Liliana,Marenzi Roberta,Ghidelli Nicola,Corbetta Andrea,Vairini Marta,Franzin Michela,Fagiuoli Stefano,Donadoni Paolo,Riglietta Marco

Abstract

Introduction: The Addictive Behaviour Centre (Ser.D.) of Bergamo has been in the frontline to tackle HCV infection in patients who use drugs over the last few years. Methods: Several initiatives have been implemented, from the HCV screening performed for the IST screening and by using finger tests, up to the prescription of direct-acting antivirals (DAAs) in the Ser.D. point of care. Results: out of 584 patients tested for HCV Ab for the IST screening, 15,4% resulted positive, out of 191 patients tested for HCVRNA, 43,5% resulted positive. Out of 186 patients tested by the use of finger tests for HCV Ab, 18,8% resulted positive, while of the 303 patients tested by HCVRNA finger test, 21,5% was positive. 94 patients were found eligible for DAAs treatment: 31 already started the treatment, while 15 are going to start in the next months. Conclusion: The access to HCV care for people who use drugs has been improved by the introduction of point of care testing and the DAAs treatment in the Ser.D. of Bergamo. Unfortunately, there are still barriers to treatment that need to be addressed for this vulnerable group of people.

Publisher

Franco Angeli

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference12 articles.

1. World Health Organization (2017). Action plan for the health sector response to viral hepatitis in the WHO European Region.

2. (2) Regione Lombardia (2021). -- Text available at the website: www.regione.lombardia.it/wps/portal/istituzionale/HP/istituzione/Giunta/sedute-delibere-giunta-regionale/DettaglioDelibere/delibera-5830-legislatura-11.

3. (3) Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., Degenhardt L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 378(9791): 571-83.

4. (4) Sperle I., Hedrich D., Palczak K., Singleton N., Zimmermann R. (2018). Barriers to HCV Testing in Drug Treatment Services for People who Inject Drugs. Poster EMCCDA Lisbon.

5. (5) EMCDDA (2019). Hepatitis C new model of care for drug services. -- Text available at the website: www.emcdda.europa.eu/drugs-library/hepatitis-c-new-models-care-drugs-services_en.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3